Medication info
Lureka OD Tablet 150 mg (Pregabalin)

Lureka OD Tablet 150 mg (Pregabalin)

Prescription medicationOrally disintegrating Tablet
Ingredient · strength
Pregabalin›150mg / 1 tablet
Manufacturer / importer
Huons BioScience Co., Ltd.
Appearance
Pink oval orally disintegrating tablet
Packaging
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Approval status
Active

MFDS item code 202600535 · Approved 2026.02.24

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who uses it
Adults · Children
Adult dosage
This medicine should be administered orally as pregabalin in 2 divided doses per day, regardless of food. Place it on the tongue and, once it has disintegrated, swallow without water. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) Peripheral neuropathic pain — Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. Central neuropathic pain — Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) Epilepsy — Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Patients with renal impairment: After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered once. No dose adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Huons BioScience Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medicine is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in epilepsy patients and is effective even when there are secondary generalized symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. Thus, it is used for various neurological disorders, ranging from neuropathic pain to epilepsy and chronic pain syndrome.

Dosage and Administration

Adult dosage

This medicine should be administered orally as pregabalin in 2 divided doses per day, regardless of food. Place it on the tongue and, once it has disintegrated, swallow without water. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) Peripheral neuropathic pain — Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. Central neuropathic pain — Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) Epilepsy — Adults: The starting dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Patients with renal impairment: After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered once. No dose adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts and behaviors; therefore, during treatment, if symptoms of depression, mood changes, or unusual behavior occur, medical personnel should be informed immediately. Patients with an allergy to any ingredient in this medication should not take it, and diabetic patients should be careful as blood sugar control may be required due to weight gain. If serious allergic reactions like angioedema occur, the medication should be stopped immediately and medical advice should be sought. Elderly patients should exercise caution as there is a risk of falls due to dizziness or drowsiness; visual changes such as blurred vision may also occur. When combined with other antiepileptic medications, withdrawal symptoms may appear upon stopping the medication, so medical advice should be followed. There is a risk of drug abuse, so patients with a psychiatric history should be particularly cautious and should be monitored for signs of drug misuse or dependence. Patients with reduced kidney function may require dose adjustments, and it should be administered with caution to patients with heart failure. When taken with opioids, increased central nervous system depressant effects may occur, necessitating caution, especially in patients with respiratory diseases or the elderly due to the risk of respiratory depression. Due to the risk of fetal malformation in early pregnancy, women of childbearing age should use effective contraception, and during pregnancy, the risks and benefits for both the mother and fetus should be carefully considered. During breastfeeding, since this medication may pass into breast milk, consideration should be given to stopping breastfeeding or the medication. Activities like driving or operating machinery should be avoided after taking this medication due to potential dizziness or drowsiness. If serious rashes or allergic symptoms develop while taking this medication, stop the medication immediately and consult with medical personnel. In cases of overdose, confusion, drowsiness, depression, seizures, etc., may occur, necessitating immediate emergency treatment. Keep out of reach of children and do not transfer to other containers for safety.

Side effects

Suicidal impulses, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial edema, periorbital edema, upper respiratory edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, suicidal thoughts, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, sexual hypersensitivity, agitation, mood swings, emotional lability, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, coordination disorders, equilibrium disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, language disorders, clonic contractions, reflex suppression, movement disorders, psychomotor agitation, positional vertigo, hypersensitivity, burning sensation, activity tremors, syncope, confusion, hypotonia, olfactory disturbances, loss of taste, writing disorders, diplopia, visual field loss, visual field defects, photophobia, dry eyes, conjunctival swelling, decreased vision, eye pain, eye fatigue, increased lacrimation, ocular irritation, mydriasis, changes in depth perception during vibration, strabismus, brightness of the visual field, dizziness, auditory hypersensitivity, first-degree AV block, tachycardia, bradycardia, homonymic tachycardia, homonymic arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, vomiting, abdominal distension, constipation, dry mouth, abdominal bloating, hypersalivation, gastroesophageal reflux, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, breast enlargement, peripheral edema, edema, gait disturbances, falling, feeling intoxicated, altered sensations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, malaise, delirium, paralysis (facial paralysis), affective disorder, sedation, confusional state, agitation, restlessness, seizures, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air or moisture. It is best kept at room temperature between 1 and 30 degrees Celsius, away from extremely hot or cold areas.

Appearance and packaging

Appearance

Pink oval orally disintegrating tablet

Package unit

30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.